Member » Vice-President

Vice President Jyh-Hong Chen

Vice President Jyh-Hong Chen

Vice President Jyh-Hong Chen

Contact

 

Current Position

  • Vice President, China Medical University
  • Dean and Professor, College of Medicine, China Medical University
  • Consultant and Attending Physician, China Medical University Hospital 

 

Education

Year Education
1983-1987 Ph.D. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
1970-1977 M.D. National Taiwan University, College of Medicine

 

Previous Position

Year Previous Position
2003-2009 Superintendent, NCKU Hospital
1990-1998 Vice-Superintendent for Teaching and Research, National Cheng-Kung University Hospital
1989-1996 Chairman, Department of Medicine, National Cheng-Kung, University Hospital, Tainan, Taiwan
1993/4-1993/6 The Johns Hopkins University Medical School, Visiting Professor
1996/2-1996/6 The William Harvey Research Institute, Visiting Professor, London
2010-2012 President, Taiwan Society of Cardiology
2013-2015 Vice-President Asian Pacific Society of Cardiology

 

Awards

Year Honors And Awards
1989 Best Teacher of the Year, National Cheng-Kung University, Ministry of Education, Executive Yuan, Taipei, Taiwan, R.O.C.
1990 Excellent Research Awards, National Science Council, Executive Yuan, Taipei, Taiwan, R.O.C.
1991 Paper of the Year, National Cheng-Kung University Medical College
1991 Paper of the Year, The Republic of China Society of Cardiology, Taipei
1993 Fellow of the American College of Cardiology (F.A.C.C.)
  Best Teacher of the Year, National Cheng-Kung University Medical College
1994 William Harvey Glaxo Scholarship
1999 Research Awards A, National Science Council, Executive Yuan, Taipei, Taiwan, R.O.C.
2000 Research Awards A, National Cheng-Kung University Medical College
2007 Research Awards A
2007 National Quality Award
2008 Taiwan Business Awards

 

Specialty

  • High Blood Pressure
  • Coronary Artery Disease
  • Angicsclerosis
  • Atrial fibrillation

 

Publication

SELECTED PUBLICATIONS
TSAI WC, LI YH, LIN CC, CHAO TH and CHEN JH* (2004) Effects of oxidative stress on endothelial function after a high-fat meal. Clinical Science;106: 315-319.
LIU PY, LI YH, TSAI WC,TSAI LM, CHAO TH, WU HL and CHEN JH* (2005) Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature myocardial infarction. Journal of Thrombosis and Haemostasis:JTH;3: 1998-2005.
LIU PY, LI YH, WU HL, CHAO TH, TSAI LM, LIN LJ, SHI GY and CHEN JH* (2006) Platelet-activating factor-acetyl hydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. Journal of thrombosis and   haemostasis : JTH ;4: 1023-1028.
LIU PY, LI YH, CHANG SH, LIN LJ, WU HL, SHI GY and CHEN JH* (2006) Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. The American journal of cardiology ;98: 1012-1017.
TSAI WC, LI YH, HUANG YY, LIN CC, CHAO TH and CHEN JH* (2006) Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clinical Science; 109: 39-43.
LIU PY, LI LH, CHAO TH, WU HL, LIN LJ, TSAI LM and CHEN JH* (2007) Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis. 195: 199-206.
LIU PY, CHEN JH, LIN LJ and James K. LIAO, (2007). Incerased Rho kinase (ROCK) activity in a taiwanese population with metabolic syndrome. J Am Coll Cardiol. 49(15) 1619-1624.
The ONTARGET Investigators (JH Chen is one of the members of steering committee), (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008;358:1547-59.
The TRANSCEND Investigators (JH Chen is one of the members of steering committee), (2008). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008:372:1174-83.
LIU PY, LIU YW, LIN LJ, CHEN JH, LIAO JK*,(2008). Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on ROCK Activity, Endothelial Function, and Inflammation. Circulation. 2009 Jan 6;119(1):131-8.
Sruart J Connolly, Michael D. Ezekowitz, Salim Yusuf, D.Phil., john Eikelboom, Jonas Oldgren, Amit Parekh, Janice Pogue, Paul A. Reilly, Ellison Themeles, Jeanne Varrone, Susan Wang, Marco Alings, Denis Xavier, Jun Zhu, Rafael Diaz, Basil S. Lewis, Harald Darius, Hans-Christoph Diener, Campbell D. Joyner, Lars Wallentin, and the RE-LY Steering Committee and Investigators, (JH Chen is one of the members of steering committee) (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.